Ebola je ubila više od 400 ljudi u Kongu, WHO najavljuje početak kliničkog ispitivanja
An outbreak of Ebola in the Democratic Republic of Congo (DRC) has resulted in over 400 deaths, according to the latest report released on July 2. The epidemic, which began on May 15 and is caused by the Bundibugyo virus, continues to spread, with a recent confirmed case in Kisangani, a major city in the northeast. There is currently no vaccine or treatment available for this strain of Ebola. The World Health Organization (WHO) has launched a clinical trial to develop a potential treatment, marking a significant step in the response efforts. As of now, 438 deaths and 1,406 cases have been reported, resulting in a fatality rate of 31.2%. The outbreak is primarily concentrated in the Ituri province, bordering South Sudan and Uganda, and nearby regions in North and South Kivu. While no new cases have been reported in Uganda since June 21, a case of Marburg fever, similar to Ebola, was detected. The DRC president emphasized the need for cross-border health cooperation, highlighting the importance of international support amid declining aid. A recent UNDP report estimates the outbreak could cost up to $3.6 billion across Africa.
Nastavljajuća epidemija ebole u Demokratskoj Republici Kongo (DRC) potaknula je Svjetsku zdravstvenu organizaciju (WHO) da pokrene kliničko ispitivanje s ciljem razvoja učinkovitih tretmana za soj virusa Bundibugyo. To označava značajan korak u globalnoj borbi protiv ebole, jer za ovu posebnu varijantu ne postoje specifična cjepiva ili tretmani.
Inicijativa dolazi usred rastuće zabrinutosti zbog širenja virusa, s 1.406 potvrđenih slučajeva i 438 zabilježenih smrtnih slučajeva do sada, što znači stopu smrtnosti od oko 31 posto.
Ispitivanje je započelo upisanjem prvog pacijenta, kako je izjavio generalni direktor WHO-a Tedros Adhanom Ghebreyesus tijekom konferencije za novinare.
Prema Vasee Moorthy, šefu WHO-a za istraživanje i razvoj, očekuje se da će ispitivanje trajati nekoliko mjeseci i potencijalno se proširiti na sljedeću godinu. Organizacija je osigurala dovoljne količine dva lijeka za liječenje do 1.200 pacijenata, osiguravajući odgovarajuću opskrbu za vrijeme trajanja studije.
Međutim, odgovor na epidemiju suočava se s brojnim izazovima, uključujući regionalne sukobe i postojeće humanitarne krize. Tedros je istaknuo da epidemija nastavlja rasti, s prosjekom 38 novih slučajeva prijavljenih dnevno tijekom posljednja dva tjedna. Unatoč poboljšanjima u praćenju kontakata, s četiri od pet kontakata koji se prate, identifikacija dodatnih kontakata ostaje hitno pitanje.
Trenutno je na raspolaganju 650 kreveta u 22 zdravstvena centra, a gotovo su svi zauzeti, a planira se dodatnih 300 kreveta za buduću upotrebu.
Nedavno je napadnut centar za liječenje ebole u Ituriju, što je dovelo do smrti dvije osobe i prisiljavanja pacijenata na bijeg. Takvi napadi ne samo da ugrožavaju živote pacijenata i zdravstvenih radnika, već i ometaju suzbijanje epidemije.
Ova situacija naglašava važnost međunarodne suradnje i prekogranične zdravstvene suradnje. Predsjednik Demokratske Republike Kongo Felix Tshisekedi naglasio je stratešku nužnost transnacionalnih zdravstvenih partnerstava tijekom konferencije za novinare uz predsjednika Južne Afrike Cyrilla Ramaphosea.
Pojavljivanje epidemije ebole poklapa se s većim izazovima s kojima se suočavaju nevladine organizacije zbog smanjenja međunarodne pomoći. Osim toga, otkrivanje slučaja virusa Marburg u Ugandi dodaje još jedan sloj složenosti krajoliku javnog zdravstva. Dok se DR Kongo bori s ovim višestrukim izazovima, WHO-ovo ispitivanje predstavlja ključni napor da se pronađu učinkoviti tretmani za soj Bundibug, pružajući nadu u smanjenje stope smrtnosti i poboljšanje ishoda za pogođene zajednice.
The World Health Organization announced the start of a clinical trial for two potential treatments for the Bundibugyo strain of Ebola in the Democratic Republic of Congo (DRC). The trial involves the monoclonal antibody MBP134 and the antiviral drug remdesivir, testing them individually and in combination. As of the latest data, there have been 1,406 confirmed cases and 438 confirmed deaths, with 208 recoveries. The trial will begin in Ituri province and may require over 1,000 participants, potentially lasting several months. WHO officials emphasized the importance of ensuring access to effective treatments post-trial. The outbreak faces challenges including limited treatment capacity and ongoing conflicts in the region.
Procjena pristranosti (Sredina): The article presents factual information about a medical trial without overtly favoring any political ideology. While the subject matter relates to public health policy, the framing remains neutral, focusing on scientific progress and humanitarian efforts rather than partisan agendas. The emphasis,措
Zašto ove ocjene (Činjenice 98 · Objektivnost 95): Highly factual with specific details on the trial, including names of treatments and methodology. Presents information objectively without emotional language. Consistent with other sources on case numbers and WHO actions.
France 24 (Français)Državni / javniSredinaČinjenice 95Objektivnost 88jučer
An outbreak of Ebola in the Democratic Republic of Congo (DRC) has resulted in over 400 deaths, according to the latest report released on July 2. The epidemic, which began on May 15 and is caused by the Bundibugyo virus, continues to spread, with a recent confirmed case in Kisangani, a major city in the northeast. There is currently no vaccine or treatment available for this strain of Ebola. The World Health Organization (WHO) has launched a clinical trial to develop a potential treatment, marking a significant step in the response efforts. As of now, 438 deaths and 1,406 cases have been reported, resulting in a fatality rate of 31.2%. The outbreak is primarily concentrated in the Ituri province, bordering South Sudan and Uganda, and nearby regions in North and South Kivu. While no new cases have been reported in Uganda since June 21, a case of Marburg fever, similar to Ebola, was detected. The DRC president emphasized the need for cross-border health cooperation, highlighting the importance of international support amid declining aid. A recent UNDP report estimates the outbreak could cost up to $3.6 billion across Africa.
Procjena pristranosti (Sredina): The article presents factual information about the Ebola outbreak and the WHO's response without overtly favoring any political stance. It includes quotes from officials and reports from international organizations but does not take a clear ideological position. The emphasis is on the medical and vi
Zašto ove ocjene (Činjenice 95 · Objektivnost 88): Factual accuracy is high, reporting confirmed case numbers and the WHO's response. The article presents information neutrally but includes some emotionally charged descriptions of the epidemic's impact. Cross-source consensus supports the reported statistics.
France 24 (English)Državni / javniSredinaČinjenice 0Objektivnost 0prije 20 h
The article appears to be a video segment from France 24, which was intended to provide coverage on the start of an Ebola treatment trial in the Democratic Republic of the Congo (DRC), as reported by the World Health Organization (WHO). However, the content is blocked due to browser extension interference, preventing the video from loading. The cover image is credited to France 24, and the publication date is March 7, 2026. No additional information or detailed content beyond the video is provided in the text.
Procjena pristranosti (Sredina): The subject matter relates to public health initiatives and international health organizations, which are generally considered low-controversy topics. While the involvement of the WHO suggests some level of governmental or institutional oversight, there is no indication of overt ideological framing.
Zašto ove ocjene (Činjenice 0 · Objektivnost 0): No content available to assess factuality or objectivity. The video embed is non-functional and provides no substantive information.
★
Neka vijesti ostanu poštene.
ObjectiveNews financiraju čitatelji i bez oglasa je – pristranost vam pokazujemo, ne skrivamo. Podržite neovisno novinarstvo za 5 €/mjesec.
France
